-+ 0.00%
-+ 0.00%
-+ 0.00%

Fulcrum Therapeutics Q1 EPS $(0.28) Beats $(0.30) Estimate. Cash And Equivalents $226.6M

Benzinga·05/01/2025 11:06:49
Listen to the news
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 34.88 percent increase over losses of $(0.43) per share from the same period last year.